Company news
Mediwound Ltd. (NASDAQ:MDWD) news
Every Mediwound Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
MediWound to Report Second Quarter 2026 Financial Results
July 29, 2026
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 27, 2026
MediWound to Report First Quarter 2026 Financial Results
May 7, 2026
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
April 13, 2026
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
April 2, 2026
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
March 5, 2026
MediWound Files Annual Report on Form 20-F
March 5, 2026
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
February 19, 2026
MediWound to Present at Upcoming Investor Conferences
February 17, 2026
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
January 12, 2026
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Inju...
December 10, 2025
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 20, 2025
MediWound to Report Third Quarter 2025 Financial Results
November 5, 2025
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
November 3, 2025
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
September 29, 2025
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
September 25, 2025
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
September 2, 2025
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 20, 2025
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg U...
August 13, 2025
MediWound to Report Second Quarter 2025 Financial Results
August 4, 2025
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 21, 2025
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
May 13, 2025
MediWound to Report First Quarter 2025 Financial Results
May 5, 2025
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
April 28, 2025
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 19, 2025
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
March 3, 2025
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
February 25, 2025
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
February 24, 2025
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
February 12, 2025
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 4, 2025
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opp...
December 17, 2024
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
November 26, 2024
MediWound to Report Third Quarter 2024 Financial Results
November 12, 2024
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
October 10, 2024
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
October 8, 2024
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal B...
August 15, 2024
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
August 14, 2024
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
August 5, 2024
MediWound to Report Second Quarter 2024 Financial Results
August 2, 2024
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
July 29, 2024
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
July 16, 2024
MediWound Announces $25 Million Strategic Private Placement Financing
July 15, 2024
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
May 29, 2024
MediWound to Report First Quarter 2024 Financial Results
May 22, 2024
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
April 25, 2024
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 21, 2024
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024